{"id":390802,"date":"2017-12-12T00:00:00","date_gmt":"2017-12-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0010-2017-biopharma-malignant-melanoma-current-treatment-physician-insights-us-2017\/"},"modified":"2026-05-10T23:27:03","modified_gmt":"2026-05-10T23:27:03","slug":"cutron0010-2017-biopharma-malignant-melanoma-current-treatment-physician-insights-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0010-2017-biopharma-malignant-melanoma-current-treatment-physician-insights-us-2017\/","title":{"rendered":"Malignant Melanoma | Current Treatment: Physician Insights | US | 2017"},"content":{"rendered":"<p>The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr>\/<abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr>-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis\u2019s Tafinlar plus Mekinist (2014), Roche\/Genentech\u2019s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb\u2019s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients\u2019 <em><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr><\/em> mutation status.<\/p>\n","protected":false},"template":"","class_list":["post-390802","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390802\/revisions"}],"predecessor-version":[{"id":393926,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390802\/revisions\/393926"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}